Drug Watch International Thwarted by the FDA
There are many anti-marijuana groups out there like Cannabis Anonymous and National Cannabis Prevention and Info Centre. A number of these groups are backed by pharmaceutical companies like Insys Therapeutics or Pfizer. They are tricky. They use their big financial backing to run negative advertisements and lobby Congress to preserve the prohibition on marijuana. Most recently it was the group Drug Watch International that aimed to put a big hurdle in front of the cannabis legalization movement.
TNMNews has spoken with cannabis legalization opponents prior to in order to offer our followers the most impartial of viewpoints. Scott Chipman, the founder of ‘People Against the Legalization of Cannabis’, was kind enough to join us for an interview prior to California legislated adult-use marijuana. His hard work to try and stop California from producing a structured cannabis market ultimately stopped working. However, that is not stopping other companies from continuing their efforts to keep cannabis as a Set up 1 compound.
What Drug Watch International attempted to do was quite smart thinking. They sent out a letter to the Fda asking for that marijuana and all of its acquired products be placed on a restricted list of substance that are not “typically acknowledged as safe and reliable.” It would not have effectively kept marijuana a Set up 1 compound, that is the DEA’s jurisdiction. Nor would it have actually stopped cannabis from being legislated in states or nationally. It would though have actually produced another barrier for marijuana business that would seek acknowledgement from the FDA.
The FDA decided the addition of marijuana and its acquired to this list of exactly what are for all intents and purposes, useless compounds, to be unneeded. Janet Woodcock, the director of the FDA’s Center for Drug Examination, responded to the request from Drug Watch International earlier today. She composed to them that adding cannabis to the list was, “not required for the protection of public health.”
The petition sent out by the ant-marijuana group was sent in December to the FDA. In the petition they talked about marketing limitations and sending out a message about the so-called medicinal benefits of marijuana. They composed that the FDA would, “send out an industry-wide warning to the estimated 33,000 cannabis services in the United States, a number of which are making unsupported medical claims for marijuana and THC drug products sold as ‘medical marijuana.’” They also wanted to, “decrease or end the capability of [over-the-counter] sellers of these drugs to assert and promote unsupported medical claims for their products.”
As to marketing, the anti-cannabis group wrote, “It would immediately make such claims unlawful and subject the sponsors to regulatory action, consisting of injunctive seizure of mislabeled and misbranded drugs, in addition to other potential sanctions allowed under the [Food, Drug and Cosmetic Act]” The FDA had this to state in action, “In order for FDA to take enforcement action versus unlawful marketing of unapproved brand-new OTC drugs consisting of marijuana or THC, it is not needed for FDA to develop a negative essay for marijuana or THC.”
The direct action from the FDA suggests that it is not thinking about hindering the development of the marijuana legalization motion. It also recommends that the Trump administration might even be interested in assisting in the motion.